Company Overview - Boundless Bio is a clinical-stage oncology company focused on developing therapies for patients with oncogene amplified cancers, addressing a significant unmet medical need [3] - The company is investigating extrachromosomal DNA (ecDNA), which is implicated in oncogene amplification in 14% to 17% of cancer patients [3] Product Development - Boundless Bio is developing its first ecDNA-directed therapeutic candidate, BBI-355, an oral inhibitor of checkpoint kinase 1 (CHK1), currently in a Phase 1/2 clinical trial [3] - The next therapeutic candidate, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) and has been evaluated in a Phase 1/2 clinical trial for cancer patients with resistance gene amplifications [3] - The company is also conducting IND-enabling studies for BBI-940, a potentially first-in-class orally bioavailable Kinesin degrader [3] Upcoming Events - Zachary Hornby, President and CEO of Boundless Bio, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 9:20 a.m. ET [1][2]

Company Overview - Boundless Bio is a clinical-stage oncology company focused on developing therapies for patients with oncogene amplified cancers by targeting extrachromosomal DNA (ecDNA), which is implicated in 14 to 17% of cancer cases [3]. - The company is developing its first ecDNA-directed therapeutic candidate, BBI-355, an oral inhibitor of checkpoint kinase 1 (CHK1), currently in a Phase 1/2 clinical trial [3]. - Boundless Bio utilizes its Spyglass platform for additional programs that are in preclinical development and discovery [3]. Upcoming Events - Zachary Hornby, President and CEO of Boundless Bio, will participate in a fireside chat at Leerink's Global Healthcare Conference on March 12, 2025, at 11:20 a.m. ET in Miami, FL [2]. - A live and archived webcast of the session will be available on Boundless Bio's website under the "Events & Presentations" section [2].